Isis Pharmaceuticals Company Profile

12:45 EDT 20th June 2018 | BioPortfolio

Isis Pharmaceuticals, Inc. is a leading drug discovery and development company, focused exclusively on the therapeutic target, RNA. Founded in 1989, Isis' mission is to develop products from its RNA-based technologies, such as antisense. Very little was known about antisense when the Company was first established, but its founders envisioned an opportunity to revolutionize the pharmaceutical industry with a more efficient and targeted means of drug discovery. Since then, Isis scientists have made tremendous progress advancing the science of antisense, unveiling capabilities that have far exceeded their expectations. Antisense drugs are the first class of drugs targeted to control expression of genes through interactions with RNA. The goal of antisense drugs is to intervene at the RNA level to prevent the production of proteins involved in disease. Antisense drugs are designed to complement and bind (hybridize) to a segment of messenger RNA (mRNA) to form a duplex. mRNA contains instructions to make proteins, including those involved in disease. The formation of this duplex or two stranded molecule prevents the RNA from functioning normally and from producing a specific protein. Antisense drugs are designed to interact specifically with the intended mRNA target. This high degree of specificity may make antisense drugs more effective and less toxic than traditional drugs. Beyond antisense, Company scientists have created another technology that exploits their knowledge of RNA. Ibis Biosciences, Inc., a wholly owned subsidiary of Isis, has developed and is commercializing the Ibis T5000 Biosensor System for rapid identification and characterization of organisms.


1896 Rutherford Road
United States of America


Phone: 760.931.9200
Fax: 760.603.2700

News Articles [514 Associated News Articles listed on BioPortfolio]

Clinical Trials of Isis 2503 Anticancer Compound Initiated

Isis Pharmaceuticals (Carlsbad, CA) has initiated a Phase II clinical trial of Isis 2503, its third antisense anticancer compound in clinical development...

Where the U.S. stands in the fight against ISIS

In 2017, President Donald Trump expanded the war on ISIS, leading to group losing former strongholds Mosul and Raqqa. But there were also American casualties in new battlefields: 21 service members ki...

Trump won’t seek new authority for wider Syria mission after hammering ISIS

The U.S. mission in Syria is shifting away from defeating the ISIS on the battlefield, but the president does not plan to ask Congress for new war powers there.

How Sunnis' post-ISIS crisis is leading some to a new Iraqi nationalism

While unbridled joy has greeted the defeat of the so-called Islamic State across Iraq, the wreckage left behind includes severe trauma to Iraq’s Arab Sunnis – leaving the minority community facing...

2018 ISIS fight to rely more on general forces

Secretary of Defense James Mattis previewed what’s next in the fight against ISIS, telling reporters that the U.S. will rely less on special forces and more on general forces, especially in Africa. ...

British Isis fighters known as 'the Beatles' captured in Syria

The pair were captured by the American-backed Syrian Democratic Forces, reports said. Two British Isis militants implicated in brutal acts of torture and execution, have been captured by US-backed Ku...

Donald Trump has made clear he wants to send 'bad dudes' to Guantanamo Bay - will the Isis 'Beatles' end up there?

Britain may be tempted to “outsource” the prosecution of two Isis fighters captured in Syria to the US, where it has often been easier to secure terror convictions, experts believe. The US milita...

Last two of British Isis jihadists known as 'the Beatles' 'captured in Syria'

Two British Isis jihadis who were part of a group known for its torture and killing of Western hostages have reportedly been captured by Syrian Kurdish fighters allied to the US. American officials s...

Drugs and Medications [307 Associated Drugs and Medications listed on BioPortfolio]

Oxygen [Isis Medical, Inc.]

Pur-wash [Niagara Pharmaceuticals Inc.]


Bacitracin [Qualitest Pharmaceuticals]

Bacitracin Ointment, USP

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash Purified Water, 98.3% Ophthalmic Solution Eyewash

Antacid [Major Pharmaceuticals]

Major Pharmaceuticals Antacid Tablets Drug Facts

PubMed Articles [147 Associated PubMed Articles listed on BioPortfolio]

Online extremism and the communities that sustain it: Detecting the ISIS supporting community on Twitter.

The Islamic State of Iraq and ash-Sham (ISIS) continues to use social media as an essential element of its campaign to motivate support. On Twitter, ISIS' unique ability to leverage unaffiliated sympa...

Injury and death during the ISIS occupation of Mosul and its liberation: Results from a 40-cluster household survey.

Measurement of mortality and injury in conflict situations presents many challenges compared with stable situations. However, providing information is important to assess the impact of conflict on pop...

Considering the ethics of big data research: A case of Twitter and ISIS/ISIL.

This is a formal commentary, responding to Matthew Curran Benigni, Kenneth Joseph, and Kathleen Carley's contribution, "Online extremism and the communities that sustain it: Detecting the ISIS support...

Associations between dairy cow inter-service interval and probability of conception.

Recent research has indicated that the interval between inseminations in modern dairy cattle is often longer than the commonly accepted cycle length of 18-24 days. This study analysed 257,396 insemina...

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Clinical Trials [266 Associated Clinical Trials listed on BioPortfolio]

A Double Blind, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 353512 Administered Intravenously and Subcutaneously to Healthy Volunteers

The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of ISIS 353512, to evaluate the blood concentration and rate elimination of ISIS 353512 fr...

The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes

To evaluate the efficacy and safety of ISIS 2922 in AIDS patients with Cytomegalovirus ( CMV ) retinitis who are unresponsive or intolerant to ganciclovir and/or foscarnet but are otherwis...

Dose-Escalating Safety Study in Subjects on Stable Statin Therapy

The aim of this study is to assess the safety of varying doses of ISIS 301012 in subjects on Stable statin therapy.

Study of ISIS 301012 in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy

The aim of this study is to assess the safety and efficacy of varying doses of ISIS 301012 as add-on therapy in subjects with Heterozygous Familial Hypercholesterolemia

A Study of Multiple Doses of ISIS SMNRx (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

The primary objective of the study is to examine the efficacy of multiple doses of ISIS SMNRx (ISIS 396443) administered intrathecally in preventing or delaying the need for respiratory in...

Companies [1329 Associated Companies listed on BioPortfolio]

Excaliard Pharmaceuticals, Inc.

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration o...

Isis Innovation

Isis Innovation is the technology transfer company of the University of Oxford, commercialising the research generated by University researchers and owned by the University.Isis Innovation Ltd is a wh...

Isis Parenting Inc.

Isis Parenting is the nation’s leading provider of prenatal and early parenting education. Isis partners with leading healthcare institutions to offer over their patients ove...

Isis Pharmaceuticals, Inc.

Isis Pharmaceuticals

Isis Pharmaceuticals, Inc. is a leading drug discovery and development company, focused exclusively on the therapeutic target, RNA. Founded in 1989, Isis' mission is to develop products from its RNA-b...

More Information about "Isis Pharmaceuticals" on BioPortfolio

We have published hundreds of Isis Pharmaceuticals news stories on BioPortfolio along with dozens of Isis Pharmaceuticals Clinical Trials and PubMed Articles about Isis Pharmaceuticals for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Isis Pharmaceuticals Companies in our database. You can also find out about relevant Isis Pharmaceuticals Drugs and Medications on this site too.

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Antisense therapy
Most human diseases are caused by production of abnormal proteins or malfunctioning proteins.   Antisense therapy involves inhibiting production of these proteins.  When a gene is known to cause a specific disease and the genetic sequence ...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Corporate Database Quicklinks

Searches Linking to this Company Record